AF710B — Safety, Research, Risks & Legal Status

Not medical advice. AF710B is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	ANAVEX 3-71; ANAVEX®3-71
Category	Research Chemical
Developer	Anavex Life Sciences Corp. (Nasdaq: AVXL)
Primary targets	M1 muscarinic acetylcholine receptor (PAM) + sigma-1 receptor (agonist)
Phase 1 cohort	42 healthy volunteers; dose range 5-200 mg; no serious adverse events
FDA Orphan Drug Designation	Granted for frontotemporal dementia
Current highest-stage trial	Phase 2 (schizophrenia, NCT06245213); Phase 2 planned for Alzheimer's disease and FTD
Formulation	Oral once-daily tablet (under development)
US legal status	Investigational drug (unapproved) in the United States. Not approved by the FDA for any indication. Holds FDA Orphan Drug Designation for frontotemporal dementia. Currently under active Phase 2 clinical development. Not available for human use outside of approved clinical trials. Not a dietary supplement.

What is AF710B?

AF710B (development name ANAVEX 3-71) is a small-molecule dual-target agent developed by Anavex Life Sciences Corp. It acts simultaneously as a selective positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor and as a direct agonist of the sigma-1 (sigma-1) receptor. It is under clinical investigation primarily for Alzheimer's disease, frontotemporal dementia (FTD), and schizophrenia, though no efficacy data from Phase 2 trials have been published as of the knowledge cutoff.

How it works

AF710B operates through two distinct but potentially complementary pharmacological mechanisms. First, it functions as a positive allosteric modulator at the M1 muscarinic acetylcholine receptor, which is thought to influence beta-amyloid synthesis pathways and reduce pathological tau phosphorylation - both hallmarks of Alzheimer's disease pathology. Second, it acts as a direct agonist at the sigma-1 receptor, a chaperone protein at the endoplasmic reticulum-mitochondria interface implicated in neuroprotection, neuroinflammation modulation, and cognitive function independently of the cholinergic system. The rationale is that engaging both targets simultaneously may produce additive or synergistic benefit in neurodegenerative contexts, though this remains to be demonstrated in adequately powered human trials.

Background & history

AF710B was developed as a successor compound in a series of M1/sigma-1 dual-targeting molecules. Preclinical publications beginning around 2015 demonstrated cognitive rescue effects in transgenic rodent models of Alzheimer's disease. Anavex Life Sciences, a Nasdaq-listed biopharmaceutical company (AVXL), advanced the compound into human trials, completing a Phase 1 safety study (NCT04442945) in healthy volunteers between 2020 and 2021. Anavex subsequently initiated Phase 2 trials in schizophrenia (NCT06245213) and has announced plans for Phase 2 work in Alzheimer's disease and frontotemporal dementia. The compound has received FDA Orphan Drug Designation for FTD. Research partnerships have included the Israel Institute for Biological Research.

What the research says

The evidence base is early-stage. Preclinical data from transgenic mouse (3xTg-AD) and transgenic rat models shows robust cognitive restoration, reduced amyloid burden, decreased neuroinflammation, elevated cerebrospinal fluid amyloid clearance, and increased synaptic marker expression. Notably, some animal studies reported that effects persisted after a five-week treatment washout period, though the mechanistic basis for this durability is not established. The completed Phase 1 trial enrolled 42 healthy volunteers receiving single or repeated daily doses across a range of 5-200 mg; the trial met its primary safety endpoint and reported no serious adverse events or significant laboratory abnormalities. No Phase 2 efficacy results in any indication have been published as of the knowledge cutoff. Whether the preclinical signals will translate to human benefit in Alzheimer's disease, FTD, or schizophrenia remains an open and unanswered question.

Reported effects

Cognitive deficit reversal in transgenic AD rodent models (preclinical only)
Reduced amyloid plaque burden in animal models (preclinical only)
Decreased neuroinflammatory markers in animal studies (preclinical only)
Increased cerebrospinal fluid amyloid clearance in rodent models (preclinical only)
Elevated synaptic marker expression in preclinical settings
Well tolerated in Phase 1 healthy volunteer cohorts; no efficacy signals from human trials yet

Dosing & administration (informational)

Published Phase 1 data tested single and repeated daily doses across a range of 5 mg to 200 mg in healthy adult volunteers. These figures are reported here for informational and literature-reference purposes only. They do not constitute a protocol, a recommended dose, or clinical guidance of any kind. AF710B is an unapproved investigational drug. No clinically validated dosing regimen exists for any indication. Do not use outside of a clinical trial. Consult a qualified clinician and refer to trial protocols for any clinical context.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Phase 1 (n=42 healthy volunteers, 5-200 mg range): no serious adverse events reported
No significant laboratory abnormalities identified in Phase 1
Oral formulation (once-daily tablet) under development; no long-term human safety data available
Safety in patient populations (Alzheimer's disease, FTD, schizophrenia) not yet established from published Phase 2 data
Animal tolerability data exist but do not reliably predict human safety
Contraindications, drug interactions, and safety in vulnerable populations (elderly, renally or hepatically impaired) are not established in the published literature
Any use outside a clinical trial setting carries unknown risk

Drug & supplement interactions

N
o
p
u
b
l
i
s
h
e
d
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
i
n
h
u
m
a
n
s
a
r
e
a
v
a
i
l
a
b
l
e
f
o
r
A
F
7
1
0
B
.
B
a
s
e
d
o
n
i
t
s
m
e
c
h
a
n
i
s
m
,
t
h
e
o
r
e
t
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
c
o
n
c
e
r
n
s
e
x
i
s
t
w
i
t
h
o
t
h
e
r
c
h
o
l
i
n
e
r
g
i
c
a
g
e
n
t
s
(
a
d
d
i
t
i
v
e
m
u
s
c
a
r
i
n
i
c
e
f
f
e
c
t
s
)
a
n
d
w
i
t
h
o
t
h
e
r
s
i
g
m
a
-
1
r
e
c
e
p
t
o
r
-
a
c
t
i
v
e
c
o
m
p
o
u
n
d
s
,
b
u
t
t
h
e
s
e
h
a
v
e
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
c
l
i
n
i
c
a
l
s
t
u
d
i
e
s
.
I
n
t
e
r
a
c
t
i
o
n
w
i
t
h
a
n
t
i
c
h
o
l
i
n
e
r
g
i
c
d
r
u
g
s
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
o
p
p
o
s
e
t
h
e
M
1
P
A
M
m
e
c
h
a
n
i
s
m
.
T
h
e
s
e
a
r
e
s
p
e
c
u
l
a
t
i
v
e
;
n
o
h
u
m
a
n
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
r
e
p
o
r
t
e
d
.

Who should avoid it

Use outside of an approved clinical trial
Concurrent use with anticholinergic medications (theoretical pharmacodynamic opposition - not clinically characterized)
Use in pregnancy or lactation (no safety data)
Use in pediatric populations (no data)
Obtaining from unregulated sources (no quality assurance possible)
Self-administration for cognitive enhancement or any other purpose (unapproved, risks unknown)

How it is commonly combined

No stacking data exist for AF710B in humans. Combination with other cholinergic agents, sigma-1 modulators, or neuropsychiatric medications has not been studied in clinical settings. Any combination use would be outside the scope of available evidence and carries entirely uncharacterized risk.

Legal & regulatory. Investigational drug (unapproved) in the United States. Not approved by the FDA for any indication. Holds FDA Orphan Drug Designation for frontotemporal dementia. Currently under active Phase 2 clinical development. Not available for human use outside of approved clinical trials. Not a dietary supplement.

Quality & harm reduction

A
F
7
1
0
B
i
s
a
n
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
p
h
a
r
m
a
c
e
u
t
i
c
a
l
c
o
m
p
o
u
n
d
d
e
v
e
l
o
p
e
d
u
n
d
e
r
G
M
P
-
c
o
n
t
r
o
l
l
e
d
c
o
n
d
i
t
i
o
n
s
b
y
a
p
u
b
l
i
c
l
y
t
r
a
d
e
d
b
i
o
p
h
a
r
m
a
c
e
u
t
i
c
a
l
c
o
m
p
a
n
y
.
I
t
i
s
n
o
t
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
.
N
o
g
r
a
y
-
m
a
r
k
e
t
o
r
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
q
u
a
l
i
t
y
s
t
a
n
d
a
r
d
s
a
p
p
l
y
i
n
a
m
e
a
n
i
n
g
f
u
l
s
e
n
s
e
;
a
n
y
m
a
t
e
r
i
a
l
o
b
t
a
i
n
e
d
o
u
t
s
i
d
e
o
f
a
s
a
n
c
t
i
o
n
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
w
o
u
l
d
h
a
v
e
n
o
q
u
a
l
i
t
y
a
s
s
u
r
a
n
c
e
,
u
n
k
n
o
w
n
p
u
r
i
t
y
,
a
n
d
n
o
e
s
t
a
b
l
i
s
h
e
d
s
a
f
e
t
y
p
r
o
f
i
l
e
f
o
r
h
u
m
a
n
u
s
e
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find AF710B →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is AF710B approved for treating Alzheimer's disease or any other condition?

No. AF710B (ANAVEX 3-71) is not approved by the FDA or any other regulatory body for any indication. It holds FDA Orphan Drug Designation for frontotemporal dementia, which confers regulatory incentives but is not an approval. It remains an investigational drug in Phase 2 clinical trials.

What does the human clinical evidence actually show so far?

Phase 1 data from 42 healthy volunteers demonstrated acceptable tolerability across a 5-200 mg dose range with no serious adverse events. This establishes only preliminary human safety, not efficacy. No published Phase 2 efficacy results are available as of the knowledge cutoff. Efficacy conclusions cannot be drawn from Phase 1 safety trials.

How convincing is the preclinical data?

The animal model data - conducted primarily in 3xTg-AD transgenic mice and transgenic rats - is considered scientifically notable within its field, showing cognitive rescue, amyloid burden reduction, and neuroinflammation suppression. However, Alzheimer's disease animal models have a long history of poor translation to human benefit. Preclinical success does not predict clinical efficacy.

What is the difference between an M1 PAM and a direct M1 agonist, and why does it matter?

A positive allosteric modulator (PAM) enhances the receptor's response to its endogenous ligand (acetylcholine) rather than directly activating it. This mechanism is theorized to preserve the spatial and temporal fidelity of cholinergic signaling and may reduce the adverse effects associated with direct M1 agonists. Whether this translates to a superior clinical profile for AF710B has not been established in human trials.

Can I get AF710B to try for cognitive enhancement or Alzheimer's prevention?

AF710B is not commercially available and is not approved for human use. It can only be accessed through participation in a sanctioned clinical trial. Self-administration would involve a compound of unknown purity with no established dosing, contraindication, or interaction profile in the general population. Do not attempt to obtain or use it outside of a clinical trial context.

What conditions are being studied in Phase 2?

As of available records, Phase 2 trials are active or planned for schizophrenia (NCT06245213), Alzheimer's disease, and frontotemporal dementia. Parkinson's disease dementia has also been mentioned as a potential indication by the developer, though trial registration details for that indication were not confirmed in the available evidence.

References & further reading

PubMed: AF710B M1 muscarinic sigma-1 agonist Alzheimer disease Hall 2018 (PMID 29291374)
PubMed: AF710B novel M1 sigma-1 agonist animal models cognitive rescue 2015 (PMID 26606130)
ClinicalTrials.gov: NCT04442945 Phase 1 ANAVEX3-71 healthy volunteers safety
ClinicalTrials.gov: NCT06245213 Phase 2 ANAVEX3-71 schizophrenia
PubMed: AF710B therapeutic efficacy transgenic rodent Alzheimer model PMC4803577